Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma

LESSONS LEARNED. Combination regimen with bevacizumab (BEV) and vorinostat is well tolerated in patients with recurrent glioblastoma. Treatment of recurrent glioblastoma remains challenging as this study and others attempt to improve progression‐free survival and overall survival with BEV‐containing...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Ghiaseddin, Ashley, Reardon, David, Massey, Woody, Mannerino, Alex, Lipp, Eric S., Herndon, James E., McSherry, Frances, Desjardins, Annick, Randazzo, Dina, Friedman, Henry S., Peters, Katherine B.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2017
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5813746/
https://ncbi.nlm.nih.gov/pubmed/29133513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0501
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados